Breast, Prostate Cancer Common in Patients With COVID-19 and Cancer History
For patients hospitalized with COVID-19, prostate cancer was the most common cancer type across all databases.
For patients hospitalized with COVID-19, prostate cancer was the most common cancer type across all databases.
Lymphoma patients displayed cognitive decline 6 months after chemotherapy, both by objective assessment and self-report.
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
The occurrence rate of BIA-ALCL following breast augmentation with textured implants is variable, with the reported lifetime risk ranging from 1 in 355 to 1 in 86,029 patients.
Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
The risk for Hodgkin lymphoma (HL) is increased in association with immunosuppression, allergic disease, and eczema.
Patients with Hodgkin lymphoma who were deficient for vitamin D experienced reduced progression-free and overall survival.
Compared with white patients, Hispanic and non-Hispanic black patients had significantly poorer rates of postrelapse overall survival.
A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma (DLBCL) are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease. The study appeared online July 20, 2015, in Nature Medicine.